Pannex Therapeutics is pioneering first-in-class Panx1 blockers with the potential to transform treatment across neurology and oncology.

Our Panx1 channel blocker platform

Pannex Therapeutics leverages advanced in silico modeling and channel docking studies, utilizing the 3D structure of human Panx1 and insights from nonspecific inhibitors to design a robust platform of small molecule Panx1 blockers.

Our patent-protected platform includes hundreds of rationally designed Panx1 blockers, many validated through rigorous testing. This innovation has led to the advancement of lead candidates in high-value therapeutic areas, positioning us to address critical unmet medical needs.